Lysodase
Gaucher's Disease
National Institute of Mental Health (NIMH)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Gaucher's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Taliglucerase Alfa Protalix | Phase 4 | A |
Velaglucerase Alfa Takeda | Phase 4 | A |
Cerezyme Sanofi | Phase 4 | A |
Cerezyme Sanofi | Phase 4 | BBB |
Eliglustat Peking Union Medical College Hospital | Phase 3 | BBB |
View all 30 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →